How Investors May Respond To Bicara Therapeutics (BCAX) FDA Breakthrough Therapy Nod for Lead Immunotherapy [Yahoo! Finance]
Bicara Therapeutics Inc. (BCAX)
Company Research
Source: Yahoo! Finance
immunotherapy combination, ficerafusp alfa with pembrolizumab, for the first-line treatment of metastatic or unresectable, recurrent HPV-negative head and neck squamous cell carcinoma in patients expressing PD-L1 with a combined positive score of at least 1. This designation highlights growing recognition of HPV-negative head and neck cancer as a distinct indication with high unmet need, supported by clinical data showing a median overall survival of 21.3 months and favorable tolerability in early studies. We'll explore how the FDA Breakthrough Therapy Designation elevates Bicara's profile and accelerates its lead program's path to market. This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality What Is Bicara Therapeutics' Investment Narrative? For anyone considering Bicara Therapeutics, the big picture centers on belief in the company's potential to bring a first-in-class immunotherapy to a cancer population with high
Show less
Read more
Impact Snapshot
Event Time:
BCAX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BCAX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BCAX alerts
High impacting Bicara Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
BCAX
News
- Bicara Therapeutics Announces Publication of an Abstract with Preliminary Phase 1b Expansion Cohort Data Evaluating 750mg of Ficerafusp Alfa Weekly Plus Pembrolizumab in 1L HPV-negative R/M HNSCC at ESMO Asia 2025GlobeNewswire
- Bicara Therapeutics (NASDAQ:BCAX) had its price target raised by analysts at Wells Fargo & Company from $8.00 to $11.00. They now have an "equal weight" rating on the stock.MarketBeat
- Bicara Therapeutics (NASDAQ:BCAX) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $30.00 price target on the stock.MarketBeat
- Bicara Therapeutics GAAP EPS of -$0.67 [Seeking Alpha]Seeking Alpha
- Bicara Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update [Yahoo! Finance]Yahoo! Finance
BCAX
Earnings
- 11/10/25 - Miss
BCAX
Sec Filings
- 11/28/25 - Form EFFECT
- 11/26/25 - Form 424B5
- 11/25/25 - Form 4
- BCAX's page on the SEC website